Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1615 1624 1626 1655
This examiner grants 0% of resolved cases
Rebecca Lynn Scotland is an examiner in Tech Center 1600 and Art Unit 1615. She has 15 resolved cases. The allowance rate for these cases is 0.0 percent. This 0.0 percent figure indicates that none of the 15 resolved cases resulted in a patent grant. Practitioners can use this information to understand the current results in this docket.
The interview lift is 0.0 percent. This value shows that interviews have not been associated with an increase in the likelihood of allowance. Given that the allowance rate is 0.0 percent, the interview lift remains at 0.0 percent as well. This suggests that applicants may need to explore different strategies to overcome rejections in Art Unit 1615.
The median days to allowance is 1025. This 1025-day duration is the middle value for the time from filing to grant. For applicants, this 1025-day median is a key metric for planning the prosecution timeline. By combining the 15 resolved cases with the 1025-day median, practitioners can develop a data-grounded strategy for their applications.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18226834 | YEAST PARTICLES FOR DELIVERY OF WATER-ACTIVATED SELF-EMULSIFYING CANNABINOID FORMULATIONS | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 18618954 | ARTIFICIAL NAIL COMPOSITION CONTAINING URETHANE POLYMER PARTICLES | Final Rejection | SHOFU INC. |
| 18911389 | ORAL CARE COMPOSITIONS COMPRISING DICARBOXYLIC ACID | Non-Final OA | The Procter & Gamble Company |
| 18298435 | Personal Care Composition Containing a Biosurfactant | Final Rejection | The Procter & Gamble Company |
| 18179486 | HAIR CONDITIONING COMPOSITION | Final Rejection | The Procter & Gamble Company |
| 18840745 | COMPLEX COACERVATES OF LACTOFERRIN AND OSTEOPONTIN | Final Rejection | SOCIÉTÉ DES PRODUITS NESTLÉ S.A. |
| 18237093 | COSMETIC COMPOSITION | Non-Final OA | L’ORÉAL |
| 17922522 | METHODS AND SYSTEMS FOR ENHANCING DELIVERY OF THERAPEUTIC AGENTS TO BIOFILMS USING LOW BOILING POINT PHASE CHANGE CONTRAST AGENTS | Final Rejection | The Regents of the University of Colorado |
| 18276596 | ECO-FRIENDLY CAPSULE MANUFACTURING METHOD FOR STABLE LOADING OF ANTISEPTIC DISINFECTANT AND ECO-FRIENDLY CAPSULE MANUFACTURED THEREFROM | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18833119 | AEROSOL DEVICE CONTAINING A COMPOSITION COMPRISING A BRANCHED ALKANE, A FATTY SUBSTANCE AND A PROPELLANT | Non-Final OA | L'OREAL |
| 18626302 | COMPOSITIONS AND METHODS FOR ALTERING THE COLOR OF HAIR | Final Rejection | L'Oreal |
| 18114639 | ANHYDROUS COSMETIC COMPOSITION INCLUDING OIL AND PLATY MINERAL, AND METHODS OF USE | Final Rejection | L'OREAL |
| 18849836 | COPOLYMER, MEDICAL COMPOSITION, COATED MEDICAL DEVICE, AND METHODS RESPECTIVELY FOR PRODUCING THOSE | Non-Final OA | TORAY Industries, Inc. |
| 18715416 | COSMETIC COMPOSITION | Non-Final OA | SHISEIDO COMPANY , LTD. |
| 18260117 | NATURAL OIL-BASED PETROLATUM AND METHOD OF MAKING SAME | Non-Final OA | CARGILL, INCORPORATED |
| 18262942 | COMPOSITION FOR EXTERNAL APPLICATION | Non-Final OA | KAO CORPORATION |
| 18592423 | METHOD OF TREATING INFLAMMATION AND PHOTORECEPTOR CELL DEGENERATION IN RETINAL DEGENERATION PATIENTS | Final Rejection | The Hong Kong Polytechnic University |
| 17788554 | COMPLEX FORMULATION COMPRISING SITAGLIPTIN AND DAPAGLIFLOZIN, AND PREPARATION METHOD THEREFOR | Final Rejection | HANMI PHARM. CO.,LTD. |
| 18695023 | IMAZAMOX AND GLYPHOSATE FOR CONTROLLING DIGITARIA INSULARIS | Final Rejection | BASF AGROCHEMICAL PRODUCTS B.V. |
| 18247524 | Composition for Treating Hair and Scalp | Final Rejection | DR. KURT WOLFF GMBH & CO. KG |
| 17782566 | DEEP-LAYER REMINERALIZATION OF HYDROXYLAPATITE | Final Rejection | DR. KURT WOLFF GMBH & CO. KG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy